Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73

Slides:

Advertisements

Similar presentations

Department of Neurology, Mayo Clinic Arizona

Advertisements

Living well with dementia: more timely diagnosis and early intervention Louise Robinson Professor of Primary Care and Ageing RCGP National Clinical Champion.

ADNI PiB Amyloid Imaging Chet Mathis University of Pittsburgh.

Disclosures/Conflicts Consulting: GE Healthcare Bayer Abbott Elan/Janssen Synarc Genentech Merck.

ADNI 3 Clinical Core Plans

Alzheimer’s Disease and Biomarkers John H. Dougherty,Jr.M.D. Medical Director Cole Neuroscience Center.

Alzheimer’s Assessment Assessing the Cognitive-Linguistic effects of Alzheimer’s.

Mild Cognitive Impairment

How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.

Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.

Update Arg-ADNI Gustavo E. Sevlever, Ricardo F. Allegri (*), Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, and Arg-ADNI group. Memory and.

COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.

Grow Your Brain at Any Age Majid Fotuhi, MD PhD Howard County Office on Aging Columbia, MD March 28, 2014.

Six Steps to a Better Brain Majid Fotuhi, MD PhD March 6, 2014.

The Worldwide Epidemic of Senile Dementias- Challenges of Pre-Clinical Treatment Evolving Diagnostic Approaches Dimitrios Kapogiannis AAAS 2015 Annual.

Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.

Disclosure of research results: should policies be changed? Melanie B. Shulman, M.D., M.Phil. Clinical Associate Professor of Neurology and Psychiatry.

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar WW ADNI Washington, DC July 17, 2015.

Is It Alzheimer’s? The Latest Update on Optimal Evaluation and Treatment of Patients with Memory Loss Majid Fotuhi, MD PhD March 5, 2014.

PZP: A novel biomarker for early Alzheimer’s disease ? Diana A.T. Nijholt Department of Neurology Laboratory for Clinical and Cancer Proteomics

Understanding Mild Cognitive Impairment. Objectives Understand the concept of MCI Identify risk factors for progression to dementia Review clinical trial.

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar ADNI Steering Committee Meeting Washington, DC April.

Update Arg-ADNI Instituto de Investigaciones Neurológicas (FLENI)

PharmaCog WP5 / E-ADNI. Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED.

Alabama Brief Cognitive Screener (ABCs)

Kimiko Domoto-Reilly, MD Cognitive / Behavioral Neurology Fellow Massachusetts General Hospital & Brigham and Women’s Hospital.

We Treat Alzheimers 20 years early? Can. Clinical neurologist-Reisa Sperling 1. Is a clinical neurologist, a neuroimaging researcher. 2.Is a leading force.

NON PHARMACOLOGICAL THERAPY OF MENTAL IMAGERY AND RELAXATION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT Poptsi Ε.,1,3, Κounti F.,1,3,Τsolaki, Μ. 1,2 1.

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Intranasal Insulin Therapy for Alzheimer Disease and.

Arg-ADNI Gustavo E. Sevlever (*), Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, Ricardo F. Allegri and Arg-ADNI group. Memory and Aging Center.

DECIDE: "Scientific and Clinical Perspectives“: Claudio Babiloni (UNIFG) and Giovanni Frisoni (IRCCS Brescia)

Update of China-ADNI Kuncheng Li, MD. PhD.

Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease Mirjana Babić.

Volume 3, Issue 4, Pages (November 2017)

C.Calia 1, L. Destino2, A. Semeraro 2, M. Pennelli 2, M. F. De Caro 2

before and after rehabilitation

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Presenter: Dr. Patricio Chrem

Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;

Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire Roos J.

An amylin analog used as a challenge test for Alzheimer's disease

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment Sanna-Kaisa Herukka,

Volume 2, Issue 1, Pages (January 2016)

Imaging AD Progression Amyloid Imaging Agents.

C.W.Ritchie, L.Flicker, A. Noel-Storr, R.McShane

Modifying Disease Course in Alzheimer's Disease

Early Dementia Distinguishing AD From MCI

Reisa Sperling, Elizabeth Mormino, Keith Johnson Neuron

Blood-Based Biomarkers in the QC Program?

ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue

AAIC 2018 Biomarker Rates of Change in Autosomal Dominant Versus “Sporadic” Alzheimer Disease John C. Morris, MD On behalf of MW Weiner, L Beckett, T.

Presenter: Dr. Patricio Chrem

Update of China-ADNI Kuncheng Li, MD. PhD.

Michael Ewers, Reisa A. Sperling, William E. Klunk, Michael W

Introduction to AD. Practical Approaches to the Identification of Alzheimer Disease in Primary Care.

Chris Hyde Exeter Test Group.

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Argentina Arg-ADNI Ezequiel Surace, PhD.

Biomarker Modeling of Alzheimer’s Disease

Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.

Figure 2 Comparison between noncarriers (−) and carriers (+) of the minor allele of rs (CYP2C19)‏ Comparison between noncarriers (−) and carriers.

HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.

Figure 2 A case of early-onset PSD

Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision.

Receiver operating characteristics curves showing discrimination between patients with dementia of the Alzheimer type (at time of diagnosis) and non-demented.

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER.

ROC curve for the TYM-MCI, ACE-R and MMSE in the separation of patients with aMCI/AD from those with SMC. ACE-R, Addenbrooke’s Cognitive Examinations;

Box plot showing the distribution of the TYM-MCI score for patients with SMC and aMCI/AD. aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease;

Presentation transcript:

Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73 Patients Followed (Baseline) Nº= 56 Patients Followed (1st year) Nº= 50 Patients Followed (30 months) Nº= 43/45 New Patients Invited to ADNI Nº= 6 Healthy Controls Nº= 15 Late MCI Nº= 16 Dementia AD Nº=13 Early MCI Nº=12 Early MCI Nº=9 Healthy Controls Nº= 14 Late MCI Nº= 16 Dementia AD Nº=11 Early MCI Nº=6 Healthy Controls Nº= 12 Late MCI Nº=15 Dementia AD Nº=10 1 Negativa 1 Negativa Patients Screened at FLENI Nº= 60 1 Cancer - 1 Negativa 1 Psiquiatrica 1 Negativa Screening Failure Nº= 7 Dropout Nº= 4 2 Claustrophobia 1 Psychiatric Disease 1 Cancer 1 Adult ADHD 2 without informant 2 removed inform.cons 1 by distance/caregiver 1 has died (cancer) 1 Negativa 1 Institucionalizada 1 Cancer 1 Negativa 1

Arg-ADNI News Healthy Controls 15 12 Early MCI 6 Late MCI 16 Follow-up 60 months Projected Follow-up Baseline Follow-up 60 month NPS Ass Alz Costs Survey MRI CSF Aβ-tau (Optional) PET PiB PET-tau AV-1451 Healthy Controls 15 12 Early MCI 6 Late MCI 16 Dementia AD 13 10 TOTAL 56 43

Arg-ADNI Results Baseline Follow-up Follow-up Healthy Controls 15 11 Total Nº NPS Ass MRI CSF Aβ-tau PET FDG PET PiB Follow-up 1 year Follow-up 30 month Follow-up 60 month Healthy Controls 15 11 13 12 2 Early MCI 7 10 8 6 1 Late MCI 16 14 Dementia AD 9 TOTAL 56 40 (71%) 53 (95%) 50 (89%) 43 5

Arg-ADNI Publications Published 2016 Creation of the Argentina-Alzheimer’s Disease Neuroimaging Initiative. Marıa Julieta Russo, Gustavo Sevlever et al. Alzheimer’s & Dementia 2014:10 S84–S87. Concordance Between 11C-PIB-PET and Clinical Diagnosis in a Memory Clinic. American Journal of Alzheimer’s Disease & Other Dementias 2015:30(6) 599-606. Cognitive reserve and Aβ1-42 in mild cognitive impairment (Argentina-Alzheimer’s Disease Neuroimaging Initiative). Paula Harris, Ricardo Allegri, et al. Neuropsychiatric Disease and Treatment 2015:11 2599–2604. Predicting episodic memory performance using different biomarkers: results from Argentina. Julieta Russo, Ricardo Allegri et al. Neuropsychiatr Dis Treat, 2016 vol. 12 pp. 2199-2206 Published 2017 Adding Recognition Discriminability Index to the Delayed Recall Is Useful to Predict Conversion from Mild Cognitive Impairment to Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative. Russo, MJ; Campos, J; Vázquez, S; Sevlever, G; Allegri, RF; Alzheimer's Disease Neuroimaging Initiative. Front Aging Neurosci, 2017 vol. 9 pp. 46

Arg-ADNI Publications In development Argentina Alzheimer’s disease neuroimaging initiative (arg-ADNI): Neuropsychology after one-year follow up. Patricio Chrem Mendez, Ricardo Allegri et al. Functional assessment in Argentina-ADNI: comparison and diagnostic utility of the Everyday Cognition (ECog) versus Functional Assessment Questionnaire (FAQ). Julieta Russo, Ricardo Allegri et al.